DRUG

#2330
Bright Minds Biosciences Inc. - common stock
88.0 7 USD
-1.82%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
88.07
88.07
Intervallo Annuale
23.18
123.75
Variazione giornaliera
-1.82%
Variazione Mensile
-1.01%
Variazione di 6 mesi
+26.27%
Variazione Annuale
+224.98%
Chiusura Precedente
89.7 0
Open
88.0 7
Minimo
88.0 7
High
88.0 7
Volume
24
Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 672.48 M
  • Employee 25
  • Founded 2017
  • CEO N/A
  • Website www.brightmindsbio.com
  • Headquarter British Columbia, Canada
  • FIGI BBG00ZKX9FP7
  • Industry Biotecnologia
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use. It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens. The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York.

Notizie